2-(2-((4-bromo-2-fluorobenzyl)carbamothioyl)-5-fluorophenoxy)acetic acid

ID: ALA395347

Chembl Id: CHEMBL395347

PubChem CID: 4369325

Max Phase: Preclinical

Molecular Formula: C16H12BrF2NO3S

Molecular Weight: 416.24

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(O)COc1cc(F)ccc1C(=S)NCc1ccc(Br)cc1F

Standard InChI:  InChI=1S/C16H12BrF2NO3S/c17-10-2-1-9(13(19)5-10)7-20-16(24)12-4-3-11(18)6-14(12)23-8-15(21)22/h1-6H,7-8H2,(H,20,24)(H,21,22)

Standard InChI Key:  JCZUIWYXULSXSW-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA395347

    Idd594

Associated Targets(Human)

AKR1B1 Tclin Aldose reductase (1404 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AKR1A1 Tchem Aldehyde reductase (91 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 416.24Molecular Weight (Monoisotopic): 414.9689AlogP: 3.66#Rotatable Bonds: 6
Polar Surface Area: 58.56Molecular Species: ACIDHBA: 3HBD: 2
#RO5 Violations: HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 3.30CX Basic pKa: CX LogP: 4.04CX LogD: 0.61
Aromatic Rings: 2Heavy Atoms: 24QED Weighted: 0.70Np Likeness Score: -1.57

References

1. Ferrari AM, Degliesposti G, Sgobba M, Rastelli G..  (2007)  Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.,  15  (24): [PMID:17870536] [10.1016/j.bmc.2007.08.019]
2. Maccari R, Ottanà R..  (2015)  Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.,  58  (5): [PMID:25375908] [10.1021/jm500907a]
3. Kousaxidis A, Petrou A, Lavrentaki V, Fesatidou M, Nicolaou I, Geronikaki A..  (2020)  Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.,  207  [PMID:32871344] [10.1016/j.ejmech.2020.112742]

Source